Literature DB >> 32569788

The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker.

Sepehr Yousefpouran1, Shayan Mostafaei2, Pegah Vahidi Manesh3, Elmira Iranifar4, Farah Bokharaei-Salim5, Javid Sadri Nahand6, Hamed Mirzaei7, Mojtaba Taran8, Farhad Babaei9, Babak Sayad10, Mohsen Moghoofei11.   

Abstract

BACKGROUND: The emerging relationship between microRNAs (miRNA) and viral-control is a topic of interest in the field of HIV. Host-genome might play an important role in the control of viremia. The aim of this study was to assess the specific miRNA profile that could contribute to the control of HIV replication in Elite Controllers.
MATERIALS AND METHODS: The expression level of miRNAs was evaluated in 6 group patients, Elite Controller (EC), HIV, HBV, HCV, HIV-HBV-HIV-HCV, and healthy controls using real-time PCR assays. Also, liver enzymes (ALT and AST) and CD4 T cell count was assessed.
RESULTS: After adequate normalization, expression level of miRNAs was determined. The expression level of miR-146 in HIV/HCV co-infected patients was the highest in all groups. The miRNAs expression profile was significantly different in patient groups compared to control and EC. Some miRNA was significantly correlated with viral load and CD4 T cell count.
CONCLUSIONS: The involvement of the mentioned miRNAs and correlation of these with viral and cellular parameters can justify the clinical outcome of all patient groups. The differentially expressed miRNA profile in patients suggests that miRNAs can be serve as biomarkers for risk of disease progression and differentiation of infections. Moreover, determining the profiles of miRNAs due to involvement of these in the pathogenesis of infection and manipulating these miRNAs could lead to opening a new gate to infection control.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Elite controller; HBV; HCV; HIV; MicroRNA

Mesh:

Substances:

Year:  2020        PMID: 32569788     DOI: 10.1016/j.micpath.2020.104355

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  9 in total

1.  MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4+ T cells.

Authors:  Nicolas Bellini; Robert Lodge; Tram N Q Pham; Jaspreet Jain; Thomas T Murooka; Alon Herschhorn; Nicole F Bernard; Jean-Pierre Routy; Cécile L Tremblay; Éric A Cohen
Journal:  iScience       Date:  2022-09-28

2.  Comparison and Correlation of Genetic Variability of the HBV Pre-S Region in HIV/HBV Co-Infected Patients: Quasispecies Perspective.

Authors:  Yuan Nie; Xizi Deng; Yun Lan; Linghua Li; Feng Li; Fengyu Hu
Journal:  Infect Drug Resist       Date:  2020-12-01       Impact factor: 4.003

3.  The expression patterns of MALAT-1, NEAT-1, THRIL, and miR-155-5p in the acute to the post-acute phase of COVID-19 disease.

Authors:  Mohammad Abbasi-Kolli; Javid Sadri Nahand; Seyed Jalal Kiani; Khadijeh Khanaliha; AliReza Khatami; Mohammad Taghizadieh; Ali Rajabi Torkamani; Kimiya Babakhaniyan; Farah Bokharaei-Salim
Journal:  Braz J Infect Dis       Date:  2022-04-25       Impact factor: 3.257

4.  Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC.

Authors:  Tahereh Donyavi; Farah Bokharaei-Salim; Hossein Bannazadeh Baghi; Khadijeh Khanaliha; Mahrokh Alaei Janat-Makan; Bahareh Karimi; Javid Sadri Nahand; Hamed Mirzaei; AliReza Khatami; Saba Garshasbi; Majid Khoshmirsafa; Seyed Jalal Kiani
Journal:  Int Immunopharmacol       Date:  2021-04-06       Impact factor: 5.714

Review 5.  MicroRNA let-7 and viral infections: focus on mechanisms of action.

Authors:  Arash Letafati; Sajad Najafi; Mehran Mottahedi; Mohammad Karimzadeh; Ali Shahini; Setareh Garousi; Mohammad Abbasi-Kolli; Javid Sadri Nahand; Seyed Saeed Tamehri Zadeh; Michael R Hamblin; Neda Rahimian; Mohammad Taghizadieh; Hamed Mirzaei
Journal:  Cell Mol Biol Lett       Date:  2022-02-14       Impact factor: 5.787

6.  Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells.

Authors:  Adrian Farid Elzarki; Seshagiri Rao Nandula; Hassan Awal; Gary L Simon; Sabyasachi Sen
Journal:  Stem Cell Res Ther       Date:  2022-03-07       Impact factor: 6.832

Review 7.  Role of miRNA dysregulation in sepsis.

Authors:  Amanda Formosa; Paul Turgeon; Claudia C Dos Santos
Journal:  Mol Med       Date:  2022-08-19       Impact factor: 6.376

Review 8.  Non-Coding RNAs and Oral Cancer: Small Molecules With Big Functions.

Authors:  Leila Erfanparast; Mohammad Taghizadieh; Ali Akbar Shekarchi
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

Review 9.  The involvement of microRNAs in HCV and HIV infection.

Authors:  Nicky Joshi; Madhuri Chandane Tak; Anupam Mukherjee
Journal:  Ther Adv Vaccines Immunother       Date:  2022-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.